Barqawi Albaha, Thompson Ian M, Crawford E David
Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
J Urol. 2004 Feb;171(2 Pt 2):S5-8; discussion S9. doi: 10.1097/01.ju.0000108141.36320.59.
We review the current status of clinical trials investigating the use of interventions designed to reduce the risk of prostate cancer.
A comprehensive review of the literature was conducted, which included the Ovid database and recent abstract proceedings from national meetings relevant to chemoprevention trials in prostate cancer. All clinical trials sponsored by the National Institutes of Health and National Cancer Institute in the United States were included.
A total of 11 randomized controlled trials were found to be currently recruiting patients in the United States. These randomized controlled trials are designed to investigate the efficacy of a variety of agents ranging from dietary supplements to laboratory manufactured drugs, such as finasteride and cyclooxygenase-2 inhibitors, for the primary chemoprevention of prostate cancer.
Chemoprevention of prostate cancer is currently being tested in a wide range of clinical trials. These studies have the potential to fundamentally alter the current approach to prostate cancer management.
我们回顾了旨在降低前列腺癌风险的干预措施的临床试验现状。
对文献进行了全面综述，包括Ovid数据库以及与前列腺癌化学预防试验相关的全国性会议近期的摘要汇编。纳入了美国国立卫生研究院和美国国立癌症研究所资助的所有临床试验。
在美国共发现11项随机对照试验目前正在招募患者。这些随机对照试验旨在研究从膳食补充剂到实验室制造的药物（如非那雄胺和环氧化酶-2抑制剂）等多种药物对前列腺癌一级化学预防的疗效。
目前正在广泛的临床试验中测试前列腺癌的化学预防。这些研究有可能从根本上改变当前前列腺癌的管理方法。
